文献速递帕金森病与运动障碍

使用18F-AV-133 VMAT2 PET影像监测帕金森病进展性黑质纹状体变性

Using 18F-AV-133 VMAT2 PET Imaging to Monitor Progressive Nigrostriatal Degeneration in Parkinson Disease.
PubMed 文献 · Neurology · 2023-11-27

本研究对帕金森病(PD)患者、快速眼动睡眠行为障碍(RBD)患者及神经科对照(NC)间隔约26个月进行两次18F-AV-133 VMAT2 PET扫描,发现PD患者三个感兴趣区PET信号均显著下降,提示VMAT2水平降低和持续神经变性;轨迹模型提示PD神经变性约持续33年,临床诊断前约20年即已发生黑质纹状体变性。

要点

  • 18F-AV-133 VMAT2 PET可在2年窗口内检测PD患者黑质纹状体变性的进展。
  • 轨迹模型提示PD神经变性约持续33年,临床诊断前约20年即已发生。
  • 该研究提供IV级证据支持VMAT2 PET可检测PD患者并量化2年内进展。

核心结论

  • 在2年期间,18F-AV-133 VMAT2 PET能够检测PD患者黑质纹状体变性的进展,是识别进展为PD风险个体的敏感工具。
  • 轨迹模型提出临床诊断前存在约20年的黑质纹状体变性。
  • 这些数据表明VMAT2 PET为监测PD神经变性进展提供了敏感指标。

研究设计与样本

  • 对PD、RBD和神经科对照(NC)参与者进行18F-AV-133 PET扫描,所有参与者间隔约26个月扫描两次。
  • 以初级视觉皮层为参考区计算区域示踪剂滞留,表示为标准摄取值比,感兴趣区包括尾状核、前壳核和后壳核。
  • 扫描时进行临床评估包括UPDRSMOTOR测试、Sniffin' Sticks和医院焦虑抑郁评分。

主要发现

  • 在26个月间期内,PD参与者(N=26)三个感兴趣区PET信号均较NC(N=12)显著下降,与VMAT2水平降低和持续神经变性一致。
  • 影像轨迹计算提示PD神经变性约持续33年[CI: 27.2-39.5]。
  • 后壳核变性在VMAT2 PET可检测前约持续10.5年[CI: 9.1-11.3],至症状发作约再6.5年[CI: 1.6-12.7],至临床诊断约再3年[CI: 0.3-8.7]。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: There are limited validated biomarkers in Parkinson disease (PD) which substantially hinders the ability to monitor disease progression and consequently measure the efficacy of disease-modifying treatments. Imaging biomarkers, such as vesicular monoamine transporter type 2 (VMAT2) PET, enable enhanced diagnostic accuracy and detect early neurodegenerative changes associated with prodromal PD. This study sought to assess whether 18F-AV-133 VMAT2 PET is sensitive enough to monitor and quantify disease progression over a 2-year window. METHODS: 18F-AV-133 PET scans were performed on participants with PD and REM sleep behavior disorder (RBD) and neurologic controls (NC). All participants were scanned twice ∼26 months apart. Regional tracer retention was calculated with a primary visual cortex reference region and expressed as the standard uptake volume ratio. Regions of interest included caudate, anterior, and posterior putamen. At the time of scanning, participants underwent clinical evaluation including UPDRSMOTOR test, Sniffin' Sticks, and Hospital Anxiety and Depression Score. RESULTS: Over the 26-month interval, a significant decline in PET signal was observed in all 3 regions in participants with PD (N = 26) compared with NC (N = 12), consistent with a decrease in VMAT2 level and ongoing neurodegeneration. Imaging trajectory calculations suggest that the neurodegeneration in PD occurs over ∼33 years [CI: 27.2-39.5], with ∼10.5 years [CI: 9.1-11.3] of degeneration in the posterior putamen before it becomes detectable on a VMAT2 PET scan, a further ∼6.5 years [CI: 1.6-12.7] until symptom onset, and a further ∼3 years [CI: 0.3-8.7] until clinical diagnosis. DISCUSSION: Over a 2-year period, 18F-AV-133 VMAT2 PET was able to detect progression of nigrostriatal degeneration in participants with PD, and it represents a sensitive tool to identify individuals at risk of progression to PD, which are currently lacking using clinical readouts. Trajectory models propose that there is nigrostriatal degeneration occurring for 20 years before clinical diagnosis. These data demonstrate that VMAT2 PET provides a sensitive measure to monitor neurodegenerative progression of PD which has implications for PD diagnostics and subsequently clinical trial patient stratification and monitoring. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that VMAT2 PET can detect patients with Parkinson disease and quantify progression over a 2-year window.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Beauchamp LC, Dore V, Villemagne VL, et al. Using 18F-AV-133 VMAT2 PET Imaging to Monitor Progressive Nigrostriatal Degeneration in Parkinson Disease. Neurology. 2023. PMID: 37816639. doi:10.1212/WNL.0000000000207748

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。